| PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers M Yarchoan, LA Albacker, AC Hopkins, M Montesion, K Murugesan, ... JCI insight 4 (6), 2019 | 429 | 2019 |
| Somatic HLA class I loss is a widespread mechanism of immune evasion which refines the use of tumor mutational burden as a biomarker of checkpoint inhibitor response M Montesion, K Murugesan, DX Jin, R Sharaf, N Sanchez, A Guria, ... Cancer Discovery 11 (2), 282-292, 2021 | 163 | 2021 |
| Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer MV Negrao, F Skoulidis, M Montesion, K Schulze, I Bara, V Shen, H Xu, ... Journal for immunotherapy of cancer 9 (8), 2021 | 145 | 2021 |
| Charting co-mutation patterns associated with actionable drivers in intrahepatic cholangiocarcinoma G Kendre, K Murugesan, T Brummer, O Segatto, A Saborowski, A Vogel Journal of hepatology 78 (3), 614-626, 2023 | 56 | 2023 |
| Profiling of 3,634 cholangiocarcinomas (CCA) to identify genomic alterations (GA), tumor mutational burden (TMB), and genomic loss of heterozygosity (gLOH). MM Javle, K Murugesan, RT Shroff, MJ Borad, R Abdel-Wahab, ... Journal of Clinical Oncology 37 (15_suppl), 4087-4087, 2019 | 50 | 2019 |
| GNAS, GNAQ, and GNA11 alterations in patients with diverse cancers AJ Parish, V Nguyen, AM Goodman, K Murugesan, GM Frampton, ... Cancer 124 (20), 4080-4089, 2018 | 44 | 2018 |
| Comprehensive genomic profiling in FIGHT-202 reveals the landscape of actionable alterations in advanced cholangiocarcinoma. IM Silverman, K Murugesan, CF Lihou, L Féliz, GM Frampton, RC Newton, ... Journal of Clinical Oncology 37 (15_suppl), 4080-4080, 2019 | 34 | 2019 |
| Evolution and mutations predisposing to daptomycin resistance in vancomycin-resistant Enterococcus faecium ST736 strains G Wang, F Yu, H Lin, K Murugesan, W Huang, AG Hoss, A Dhand, LY Lee, ... PLoS One 13 (12), e0209785, 2018 | 34 | 2018 |
| Somatic HLA class I loss is a widespread mechanism of immune evasion which refines the use of tumor mutational burden as a biomarker of checkpoint inhibitor response. Cancer … M Montesion, K Murugesan, DX Jin, R Sharaf, N Sanchez, A Guria, ... CD-20-0672.[Abstract][CrossRef][Google Scholar], 0 | 31 | |
| Comparative genomic analysis of intrahepatic cholangiocarcinoma: biopsy type, ancestry, and testing patterns MA Israel, N Danziger, KA McGregor, K Murugesan, O Gjoerup, ES Sokol, ... The Oncologist 26 (9), 787-796, 2021 | 27 | 2021 |
| Clinicopathologic and genomic characterization of PD-L1-positive uterine cervical carcinoma RSP Huang, J Haberberger, K Murugesan, N Danziger, M Hiemenz, ... Modern Pathology 34 (7), 1425-1433, 2021 | 24 | 2021 |
| Clinicopathologic and genomic landscape of non-small cell lung cancer brain metastases RSP Huang, L Harries, B Decker, MC Hiemenz, K Murugesan, J Creeden, ... The Oncologist 27 (10), 839-848, 2022 | 23 | 2022 |
| Pan-cancer landscape of CD274 (PD-L1) copy number changes in 244 584 patient samples and the correlation with PD-L1 protein expression RSP Huang, K Murugesan, M Montesion, DC Pavlick, DA Mata, ... Journal for Immunotherapy of Cancer 9 (5), 2021 | 20 | 2021 |
| Tissue and liquid biopsy profiling reveal convergent tumor evolution and therapy evasion in breast cancer S Sivakumar, DX Jin, H Tukachinsky, K Murugesan, K McGregor, ... Nature Communications 13 (1), 7495, 2022 | 16 | 2022 |
| The Co‐mutational Spectrum Determines the Therapeutic Response in Murine FGFR2 Fusion‐Driven Cholangiocarcinoma G Kendre, S Marhenke, G Lorz, D Becker, T Reineke‐Plaaß, T Poth, ... Hepatology 74 (3), 1357-1370, 2021 | 16 | 2021 |
| Covalent ERα antagonist H3B-6545 demonstrates encouraging preclinical activity in therapy-resistant breast cancer C Furman, X Puyang, Z Zhang, ZJ Wu, D Banka, KB Aithal, LA Albacker, ... Molecular Cancer Therapeutics 21 (6), 890-902, 2022 | 15 | 2022 |
| PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers. JCI Insight 2019; 4 (6): e126908 M Yarchoan, LA Albacker, AC Hopkins, M Montesion, K Murugesan, ... Figures legends, 0 | 15 | |
| Genomic profiling of combined hepatocellular cholangiocarcinoma reveals genomics similar to either hepatocellular carcinoma or cholangiocarcinoma K Murugesan, R Sharaf, M Montesion, JA Moore, J Pao, DC Pavlick, ... JCO precision oncology 5, 1285-1296, 2021 | 14 | 2021 |
| IDH1 and IDH2 Driven Intrahepatic Cholangiocarcinoma (IHCC): A comprehensive genomic and immune profiling study. S Makawita, MJ Borad, F Carapeto, L Kwong, TS Bekaii-Saab, ... Journal of Clinical Oncology 39 (15_suppl), 4009-4009, 2021 | 13 | 2021 |
| Durable responders in advanced NSCLC with elevated TMB and treated with 1L immune checkpoint inhibitor: a real-world outcomes analysis RSP Huang, DP Carbone, G Li, A Schrock, RP Graf, L Zhang, ... Journal for Immunotherapy of Cancer 11 (1), 2023 | 12 | 2023 |
